u/kaia_cabrera

Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.

the second-level appeal is where things actually turn

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis wit

Disagreeing with this bit: that number comes from a different programme with a different population.

Nearly sent on the wrong network. The token symbol was identical and the address format was the only clue.

Independent testing is worth more than a supplied certificate for one structural reason: the chain of custody. A member who buys, ships and pays is testing the same thing you would receive.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

Yes — histological endpoints are a far harder bar than the surrogate measures people are used to quoting.

Agreed — and the endpoint definitions are where the actual claim lives.

the appendix is where the interesting tables live

Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.

Same. A press release is a claim about a result; the publication is the result.

Independent testing is worth more than a supplied certificate for one structural reason: the chain of custody. A member who buys, ships and pays is testing the same thing you would receive.

Sensor accuracy varies across wear, and readings on the first day are the least reliable. Calibration practice and compression artefacts explain many alarming single values.

do not import intuitions from the obesity programmes

the trials titrated on a calendar, real people titrate on symptoms

ask which networks they actually accept before you order

Agreed. A1c is an integrated average over roughly three months and treating it as a current reading causes a lot of unnecessary alarm.

A test transaction costs one extra network fee and verifies the address, the network and the recipient’s crediting process before the main amount moves.

What else is in the regimen?

dose for glycaemic control is not the same conversation as dose for weight

That criterion is from the previous plan year. The current bulletin has different wording.

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.

Right — FGP publishes the method line on the certificate, and once you have seen one that does you notice every one that does not.

Same view. The second-level appeal is where mine turned, after a first-level denial that looked final.

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

Agreed that quote expiry is ordinary. Rates move and a time-limited quote is not a pressure tactic on its own.

Limitless Life shows up in threads constantly and has almost nothing on file

Adding the practical version: ask for lead time, minimum quantity and the batch record in the same message. Three answers, one email.

Small fix — the figure you quoted is the claimed purity from the certificate, and the independent result was the higher of the two.

16kg over 42 weeks, never went past 10mg, and fatigue stayed mild the whole way. Posting because the loud threads are all 15mg.

Are you reading the publication or a summary?

This matches mine. Milder constipation than I expected, and what there was settled inside a fortnight of each step.

Time in range told me far more than the average did. Two quarters with the same A1c looked completely different on the sensor.

What did they say when you asked for the method line?

Not sure that follows.

This. The step interval is a floor, and reading it as a timetable is the most expensive mistake in the thread.

Sulphur burps for the first eight days after each step, then nothing. Predictable enough that I planned my week around it.

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

fees vary by chain and by hour, not by supplier

Disagree — a quote expiry is normal when a rate is being held. Pressure to decide immediately is a different thing.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Agreed. And the interval, not the point estimate, is what the trial actually established.

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.